Table 1 PVACE BOP primary therapy for poor-risk cases (SNLG index >0.5)

(a) For high-risk Hodgkin's disease

Day 1

Vinblastine (6 mgm⁻² IV)

Day 1–3

Etoposide (IV 100 mgm⁻² × 1 dose)

Oral (200 mgm⁻² × 2 doses)

Days 1–14

Procarbazine (100 mgm⁻² oral)

Days 1–14

Chlorambucil (6 mgm⁻² oral)

Day 8

Adriamycin (25 mgm⁻² IV)

Day 8

Vincristine (2 mg IV)

Day 15

Bleomycin (6 mgm⁻² IV)

Day 22

Bleomycin (6 mgm⁻² IV)

Days 14–28

Prednisolone (40 mg daily oral)

Day 29

=Day 1 of next course

(b) Ifosphamide, VP16 and epirubicin (IVE) for relapsed or progressive Hodgkin's disease

VP16

200 mgm⁻²day⁻¹ as 2 h infusion days 1–3

Epirubicin

50 mgm⁻²day⁻¹ IV day 1 (bolus)

Ifosphamide

3 gm⁻² 24 h infusions days 1–3 with MESNA cover in 2.5 l dextrose saline